List of adverse effects of pazopanib

This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence.^{[1][2][3][4][5]}

Very common

Very common (>10% incidence) adverse effects include:

• Reduced appetite
• Headache
• Taste changes
• High blood pressure^{[Note 1]}
• Diarrhoea
• Abdominal pain
• Nausea
• Vomiting
• Hair colour change
• Hand-foot syndrome
• Hair loss
• Rash
• Fatigue
• Increased alanine aminotransferase
• Increased aspartate aminotransferase
• Tumour pain^‡
• Myelosuppression^{‡[Note 2]}
• Stomatitis^‡
• Exfoliative rash^‡
• Skin hyperpigmentation^‡
• Weight loss^‡

Common

Common (1–10% incidence) adverse effects include:

• Tumour pain^†
• Myelosuppression^{†[Note 3]}
• Underactive thyroid
• Dehydration
• Low level of phosphate in the blood
• Dizziness
• Lethargy
• Paraesthesia
• Peripheral sensory neuropathy
• Blurred vision
• Hot flush
• Venous thromboembolic event
• Flushing
• Nose bleed
• Voice anomalies
• Shortness of breath
• Coughing up blood
• Stomatitis
• Indigestion
• Flatulence
• Abdominal distension
• Dry mouth
• Mouth ulceration
• Hyperbilirubinaemia
• Abnormal liver function
• Hepatotoxicity
• Skin hypopigmentation
• Dry skin
• Itchiness
• Erythema
• Skin depigmentation
• Hyperhidrosis
• Joint pain
• Muscle aches
• Muscle spasms
• Protein in the urine
• Mucosal inflammation
• Weakness
• Oedema
• Chest pain
• Weight loss^†
• Increased blood creatinine
• Lipase increased
• Decreased white blood cell count
• Blood TSH decreased
• Amylase increased
• Gamma-glutamyltransferase increased
• Increased blood pressure
• Increased blood urea
• Abnormal liver function test
• Gingival infection^‡
• Dizziness
• Insomnia
• Peripheral sensory neuropathy
• Heart dysfunction
• Blurred vision
• Low heart rate
• Left ventricular dysfunction
• Bleeding (including haemorrhage)
• High blood sugar
• Low blood sugar

Uncommon

Uncommon (0.1–1% incidence) adverse effects include:

• Torsades de pointes
• Heart failure
• Liver failure
• GI perforation (may be fatal)
• Fistula formation

Rare

Rare (<0.1% incidence) adverse effects include:

• Reversible posterior leucoencephalopathy syndrome

Notes

^† Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma.

^‡ Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.

1. Usually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment.
2. This includes leucopenia, thrombocytopenia and neutropenia.
3. This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia.

References

1. "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.
2. "VOTRIENT (pazopanib hydrochloride) tablet, film coated [GlaxoSmithKline LLC]" (PDF). DailyMed. GlaxoSmithKline LLC. November 2013. Retrieved 27 January 2014. line feed character in |title= at position 56 (help)
3. "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Retrieved 27 January 2014.
4. "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014.
5. "PRODUCT INFORMATION VOTRIENT® TABLETS" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014.